Oppenheimer analyst Mark Breidenbach maintained a Buy rating on Arvinas Holding Company (NASDAQ:ARVN) on Thursday, setting a price target of 108, which is approximately 39.26% above the present share price of $77.55.
Breidenbach expects Arvinas Holding Company to post earnings per share (EPS) of -$0.84 for the third quarter of 2021.
The current consensus among 7 TipRanks analysts is for a Strong Buy rating of shares in Arvinas Holding Company, with an average price target of $121.43.
The analysts price targets range from a high of $170 to a low of $105.
In its latest earnings report, released on 03/31/2021, the company reported a quarterly revenue of $5.54 million and a net profit of -$41.65 million. The company's market cap is $3.8 billion.
According to TipRanks.com, Oppenheimer analyst Mark Breidenbach is currently ranked with 4 stars on a 0-5 stars ranking scale, with an average return of 13.0% and a 36.86% success rate.
Arvinas, Inc. is a biopharmaceutical company, which engages in the discovery, development and commercialization of therapies to degrade disease-causing proteins. Its lead products include ARV-110 and ARV-471. The company was founded in February 2013 and is headquartered in New Haven, CT.